WO1999037784A1 - Porcine reproductive and respiratory syndrome oral vaccine production in plants - Google Patents
Porcine reproductive and respiratory syndrome oral vaccine production in plants Download PDFInfo
- Publication number
- WO1999037784A1 WO1999037784A1 PCT/CA1999/000064 CA9900064W WO9937784A1 WO 1999037784 A1 WO1999037784 A1 WO 1999037784A1 CA 9900064 W CA9900064 W CA 9900064W WO 9937784 A1 WO9937784 A1 WO 9937784A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plant
- protein
- gene
- sequence
- dna molecule
- Prior art date
Links
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 title description 44
- 238000004519 manufacturing process Methods 0.000 title description 18
- 229940126578 oral vaccine Drugs 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 147
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 50
- 241000282887 Suidae Species 0.000 claims abstract description 30
- 239000013598 vector Substances 0.000 claims abstract description 28
- 230000003053 immunization Effects 0.000 claims abstract description 10
- 230000001131 transforming effect Effects 0.000 claims abstract description 9
- 230000000241 respiratory effect Effects 0.000 claims abstract description 7
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims abstract description 4
- 238000003306 harvesting Methods 0.000 claims abstract description 4
- 230000001850 reproductive effect Effects 0.000 claims abstract description 4
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims abstract description 3
- 239000007924 injection Substances 0.000 claims abstract description 3
- 238000009304 pastoral farming Methods 0.000 claims abstract 2
- 241000196324 Embryophyta Species 0.000 claims description 126
- 230000014509 gene expression Effects 0.000 claims description 48
- 108020004414 DNA Proteins 0.000 claims description 32
- 108700005078 Synthetic Genes Proteins 0.000 claims description 30
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 28
- 102000053602 DNA Human genes 0.000 claims description 19
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 17
- 230000004048 modification Effects 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 14
- 230000014759 maintenance of location Effects 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 9
- 230000007017 scission Effects 0.000 claims description 9
- 244000061176 Nicotiana tabacum Species 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 6
- 108700007698 Genetic Terminator Regions Proteins 0.000 claims description 3
- 101710126256 Hydrolase in agr operon Proteins 0.000 claims description 3
- 240000004658 Medicago sativa Species 0.000 claims description 2
- 230000012010 growth Effects 0.000 abstract description 5
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 43
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 43
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 43
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 43
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 43
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 43
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 43
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 43
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 43
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 43
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 43
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 43
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 43
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 43
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 43
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 43
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 43
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 43
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 43
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 43
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 43
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 43
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 43
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 43
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 43
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 43
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 43
- 241000700605 Viruses Species 0.000 description 40
- 210000001519 tissue Anatomy 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 22
- 241000208125 Nicotiana Species 0.000 description 21
- 101150062176 ORF5 gene Proteins 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 230000009261 transgenic effect Effects 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 239000000427 antigen Substances 0.000 description 16
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 16
- 108020004705 Codon Proteins 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 13
- 241000219823 Medicago Species 0.000 description 12
- 108700019146 Transgenes Proteins 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000009466 transformation Effects 0.000 description 11
- 230000014616 translation Effects 0.000 description 11
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000589158 Agrobacterium Species 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 241000282898 Sus scrofa Species 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 101900328733 Porcine reproductive and respiratory syndrome virus Glycoprotein 5 Proteins 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 108700010070 Codon Usage Proteins 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000700618 Vaccinia virus Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 108700001094 Plant Genes Proteins 0.000 description 3
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 3
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940124590 live attenuated vaccine Drugs 0.000 description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108700003860 Bacterial Genes Proteins 0.000 description 2
- 101100488875 Cassava vein mosaic virus ORF 5 gene Proteins 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108700001097 Insect Genes Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 241000710789 Lactate dehydrogenase-elevating virus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000714209 Norwalk virus Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108010058731 nopaline synthase Proteins 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940027257 timentin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 241000724328 Alfalfa mosaic virus Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108010053481 Antifreeze Proteins Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 101710151559 Crystal protein Proteins 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 1
- YAHZABJORDUQGO-NQXXGFSBSA-N D-ribulose 1,5-bisphosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)C(=O)COP(O)(O)=O YAHZABJORDUQGO-NQXXGFSBSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000276572 Hemitripterus americanus Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 241000710788 Lelystad virus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000702625 Mink enteritis virus Species 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 101150005851 NOS gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000208134 Nicotiana rustica Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710087110 ORF6 protein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101710096342 Pathogenesis-related protein Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241001516645 Simian hemorrhagic fever virus Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000012677 causal agent Substances 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940088530 claforan Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000012869 germination medium Substances 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 108010083942 mannopine synthase Proteins 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000008121 plant development Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000021749 root development Effects 0.000 description 1
- 239000012882 rooting medium Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000004162 soil erosion Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000003971 tillage Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000701 toxic element Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to the production of an animal vaccine in plants. More specifically, this invention relates to the expression of at least one gene obtained or derived, from a porcine reproductive and respiratory syndrome virus. This invention also relates to the purification and administration of corresponding protein(s) to induce the production of protective antibodies in pigs.
- PRRS Porcine reproductive and respiratory syndrome
- Severe symptoms in breeding sows include abortion, premature farrowing, and stillbirths, while in piglets respiratory illness is more common causing preweaning mortality of up to 80% (Loula 1991, see Chritianson and Joo 1994 for review). Persistently infected animals may be clinically asymptomatic, but continue to shed virus and are an important source of virus transmission to naive animals. In severe outbreaks, affected breeding farms can lose an average of 10% of their annual weaner production. Direct losses from PRRS virus infection have been estimated to range from $70 to $350 per sow, and the loss of potential profits is an additional $440 per sow (Meridith 1995, Muirhead 1992, Poison 1990).
- Losses from grower/finisher pigs due to the reduced growth rate result from an increase in average time (up to 7 days) required to reach slaughter weight. Furthermore, many countries ban importation of - 2 - live pigs and semen from affected countries which has created further economic loss among Canadian pig exporters Anon 1992). It is imperative to develop appropriate control measures to prevent PRRS virus infection so that the pig industry in Canada, and particularly Ontario where there are large numbers of pig farms, remains viable and competitive.
- live vaccines contain a potential of reversion of the vaccine strain to virulence and actual disease production upon vaccination.
- inactivated killed vaccines are safe, but are generally poor in immunogenicity and require a large dose of antigen. Therefore, it is too costly to produce such vaccines specifically for veterinary use.
- Modern recombinant DNA technology will allow us to develop safe, efficacious, and cost-effective vaccines by producing recombinant subunit PRRS virus antigen in plants.
- the development of transgenic plants that contained a mammalian gene protein was a major advance in plant biotechnology (Lefebvre et al.1988).
- PRRS Porcine reproductive and respiratory syndrome
- the causal agent for PRRS has been recently isolated, and it appears to belong to a unclassified group of viruses known as the Arterivirus group (Plagemann and Meonnig 1992, Meulenberg et al. 1993). Arteriviruses also include three additional viruses: equine anemia virus, simian hemorrhagic fever virus, and lactate dehydrogenase elevating virus of mice.
- PRRS virus in pigs is an enveloped virus containing a 15 kilobase genome of single-stranded RNA with positive polarity.
- ORFs open reading frames
- ORF5 is a major structural protein that has been identified in the purified virions (Loemba et al. 1996).
- ORF6 is also a membrane protein, but it is unlikely to be an antigen for inducing a neutralizing antibody response as shown in other Arteriviruses.
- ORF2, 3, and 4 proteins are not characterized, and therefore their biological functions are largely unclear at present.
- lactate dehydrogenase elevating virus of mouse studies using monoclonal antibodies have demonstrated that the ORF5 protein is a major viral antigen inducing neutralizing antibodies (Plagemann and Moennig 1992). It has also been reported that ORF2 may play a minor role in inducing neutralizing antibody in mice.
- PRRS virus proteins in an epithelial cell, or tissue culture systems are disclosed in JP 08205858, and US 5,510, 258, respectively.
- U.S. 5,510,258 provides a tissue culture base system for the production of PRRSN.
- WO 96/04010 and WO 94/18311 a green monkey kidney cell line is used for the production of the virus, and in WO95/31550 the vaccine is produced using a baculo virus expression system.
- EP732340 discloses the production of a glycosylated form of PRRSN using a suitable host system, with the preferred host as baculovirus. This latter application is also directed to the expression of ORFS2-4.
- WO96/21012 is directed to the use of alfalfa and tobacco as a plant expression systems for producing immunoglobulins. None of the above publications disclose, or suggest, the preparation of proteins obtained from PRRS virus using a plant host.
- a bacterial antigen (E. coli enterotoxin) produced in transgenic plants was shown to effectively immunize mice when the crude protein extracts from the transgenic plant tissue were administered orally (Haq et al. 1995). Plants have also been used to produce vaccine antigens for such viral diseases as hepatitis B, and Norwalk virus (Mason et al. 1992, 1996). These antigens were orally immunogenic in mice and comparable to, in the case of the Norwalk virus antigen, to that produced by baculovirus infected insect cell cultures. Plants were transformed using Agrobacterium mediated transformation and the antigen was administered by direct feeding of plant tissue or as a crude protein extract.
- Plant derived vaccines against such animal diseases as mink enteritis virus and human diseases such as polio have been produced through the expression of viral epitopes on the surfaces of plant viruses, followed by infection with the modified virus of a susceptible host (Dalsgaar et al. 1997, Haynes et al. 1986). The plant virus is purified from the tissue and administered to the test animals. Although this system is very effective, the size of the antigen that can be produced is limited to 37 amino acids, which requires that the epitope mapping of antigen be complete (Yusibov et al. 1997)
- Tobacco Although plants have long been sources of pharmacologically active products, the advent of plant genetic engineering has created a myriad of new possibilities (Ma and Hein 1995; Goddjin and Pen 1995). Tobacco has proven itself to be particularly amenable to transformation with heterologous genes and for some time has been the model system for plant transformation (Horsch et al. 1989). Despite the fact that these crop-protection-focused biotechnologies have not found application in tobacco production, a major role does remain for tobacco as a bioreactor. Tobacco leaves are capable of producing high levels (8-10%) of soluble protein (fraction 1 protein, FIP) (Woodleif et al.
- FIP soluble protein
- Alfalfa presents some unique advantages as a bioreactor for protein production in plants. Protein levels are typically in the 20% range on a whole-plant basis and can be higher depending on management. This feature, coupled with high vegetative yields, enables a crop of alfalfa to produce more protein per hectare than any other crop in - 6 -
- alfalfa is also a perennial, a stand of alfalfa provides additional environmental benefits such as retention of snow (and moisture) in the field and reduction of wind and soil erosion; the perennial habit also eliminates the costs of tillage and planting required for annual crops.
- the present invention provides a means of low-cost production of a viral antigen protein capable of inducing production of protective antibody against PRRS virus in pigs. - 7 - SUMMARY OF THE INVENTION
- the present invention relates to the expression of an animal vaccine in plant tissue. More specifically, this invention relates to the expression of at least one gene obtained from a PRRS virus in plants and the administration of this gene product to pigs.
- a method of preparing at least one porcine reproductive and respiratory syndrome virus protein comprising the step of obtaining a gene encoding the protein, inserting the gene within a vector suitable for transforming a plant, transforming a plant with the vector, and growing the transformed plant.
- This method may use a native gene sequence, or a synthetic gene sequence.
- this invention is directed to the above method wherein the transformed plant is harvested to obtain harvested tissue, extracting the protein from the harvested tissue, and optionally purifying the protein following the step of extraction.
- This invention also provides for a protein that is prepared by this method.
- This invention is also directed to the above method, wherein the native, or synthetic gene sequence is modified in order to enhance expression of the gene and stability of the encoded protein, within plant tissues.
- This invention also includes the above method, wherein the modification includes replacing the native signal sequence with a heterologous signal sequence, an ER retention motif, a cleavage site, and a HIS tag.
- This invention also provides for a method as described above, wherein the gene encodes the ORF5 protein.
- This invention is also directed to the method described above wherein the plant is a tobacco plant or an alfalfa plant. - 8 -
- DNA molecule defined by SEQ ID NO:l is a DNA molecule defined by SEQ ID NO:l, and a vector comprising this DNA molecule operatively associated with a promoter, enhancer and terminator regions. Furthermore, this invention provides for a plant comprising the above defined vector.
- This invention is also directed to a method of immunizing pigs against porcine reproductive respiratory syndrome comprising transforming a plant with the vector defined above, growing the transformed plant, harvesting the transformed plant to obtain harvested tissue, feeding the harvested tissue to pigs, and repeating step of feeding , as needed. Also included within the provisions of this invention is the method as defined wherein a protein encoded by the DNA molecule present within the vector is extracted from the harvested tissue and administered to the pig as a food supplement, or as an injection. Furthermore, this invention is directed to administering non-harvested plant tissues to a pig.
- FIGURE 1 presents an example of the nucleotide sequence of a synthetic PRRS virus ORF5 gene. Where changes were made to the native mature protein sequence the original base is presented above.
- the PRlb secretory signal from tobacco is found from bases 1 through 93, the mature PRRS virus ORF5 coding region, from bases 94 through 621, a thrombin cleavage site from bases 622 through 636, a histidine tag from bases 649 through 666 and a KDEL motif at bases 667 through 678.
- FIGURE 2 represents an example of a simplified cloning scheme used to construct a synthetic PRRS virus ORF5 gene from oligonucleotide blocks.
- Blocks I to III represent individual oligonucleotides that are first annealed then ligated, then amplified to form DNA duplexes having unique restriction sites that allow for enzymatic assembly of the complete synthetic gene.
- a Bam HI restriction site was added to the 5' end of the sequence, and a Kpn 1 sequence added to the extreme 3' end for ease of cloning.
- the leader sequence from alfalfa mosaic virus is found from bases 10 through 45, the PRlb secretory signal from tobacco is found from bases 49 through 143, the mature PRRS virus native ORF5 protein coding region from bases 144 through 663.
- the individual base changes made as a part of the codon optimization process or to add restriction sites are exemplified as the single boldface letters above those in the native sequence.
- the thrombin cleavage site is found from bases 664 through 681, the histidine tag from bases 692 through 709 and the ER retention signal from bases 710 through 721.
- FIGURE 3 represents an example of oligonucleotide sequences used to construct one of the blocks that make up the synthetic gene. - 10 -
- FIGURE 4 shows complete sequences of primers comprising Block I, II and III, used for constructing synthetic ORF5.
- Primers 1 to 12 are SEQ ID NO's:2 to 13, respectively.
- FIGURE 5 shows Northern analysis of tobacco plants transformed with a native ORF5 gene construct (pCAMTerX-ORF5A), or a synthetic ORF5 gene construct, (pCAMTerX-ORF5B).
- Figures 5 A and B Northern blots of RNA obtained from leaf tissue of plants transformed with pCAMTerX-ORF5A.
- Figures 5 C and D Northern blots of RNA obtained from leaf tissue of plants transformed with pCAMTerX-ORF5B.
- " ⁇ " represents the molecular size marker; "81V9" the untransformed (control) plant.
- FIGURE 6 shows Western analysis of tobacco plants transformed with a synthetic gene construct (pPSP-ORF5B). Proteins were isolated from plants using standard techniques, separated using SDS-PAGE and transferred onto membrane for probing with a polyclonal antiserum specific for ORF5. The antiserum was obtained from pigs. Lane M is prestained molecular weight markers; Lane 1 an untransformed plant (control); and lanes 2 to 9 transgenic plants.
- This invention is directed to the expression of an animal vaccine in plant tissue. More specifically, this invention relates to the expression of at least one gene obtained from a PRRS virus in plants and the administration of this gene product to pigs.
- the present invention provides a means of low-cost production of a viral antigen protein capable of inducing production of protective antibody against PRRS virus in pigs.
- a gene encoding the gene of interest of a PRRS virus for example the ORF5 protein
- a synthetic gene encoding the protein of interest for example the ORF5 protein
- the native or synthetic gene may be altered or designed, as the case may be, in a way so that the corresponding protein is produced at a level higher than the native gene.
- a synthetic gene will have from about 60 - 90% homology with the native gene and to be designed, that is modified, for high level expression in plants. More preferably, the synthetic gene comprises from about 80 - 90% homology with the native gene. In the examples below, a gene comprising 82.% homology is disclosed, however, it is to be understood that this embodiment is not to be considered limiting in any manner.
- a native or synthetic gene may occur so that expression of the gene, and stability or purification of the protein can be optimized.
- modification of the 5' or 3' region of these genes can be carried out in order to enhance expression of the gene and target the product to an appropriate intercellular compartment to ensure stability.
- modification of a native gene so that both the native and the synthetic gene comprise a KDEL ER retention motif, a PRlb signal sequence, and a cleavage site and histidine tag to aid in purification of the encoded protein.
- an ORF5 protein from PRRS virus is exemplified.
- This synthetic gene has, for example, the nucleotide sequence presented in SEQ ID NO:l (also see Figure 1), however, other genes encoding ORF's of the PRRS virus, or combinations of these ORF's may easily be substituted for the exemplified synthetic gene (e.g. see Figure 1).
- the synthetic gene encoding the mature protein comprises a codon bias similar to highly expressed genes found in plants, that the protein carry a motif that allows for simple extraction, and that the immature protein is targeted to a compartment of the cell to enhance stability of the product, for example the lumen of the endoplasmic reticulum (ER).
- modified native or synthetic genes also comprise a C terminal motif that causes the encoded protein to be retained within the ER.
- ORF5 consists of 600 nucleotides which encodes a polypeptide of 200 amino acids.
- the predicted ORF5 protein contains a hydrophobic signal sequence at the N-terminus and two additional hydrophobic domains which are likely the membrane spanning region. Four putative N-linked glycosylation sites were also found in the region of first 50 amino acids.
- ORF5 sequence was engineered for insertion into the vaccinia virus genome, and we were able to construct a recombinant vaccinia virus (Yoo 1997).
- This - 13 - recombinant vaccinia virus carries the ORF5 gene in the thymidine kinase locus of the viral genome under the control of vaccinia virus late promoter.
- a polypeptide of 25 kD in molecular weight has been specifically identified. This polypeptide reacts specifically with monospecific antibody raised against the ORF5 protein produced in E. coli.
- gene it is meant a particular sequence of nucleotides including the coding region, or fragment thereof, and optionally the promoter and terminator regions which regulates expression of the gene, as well as other sites required for gene expression for example a polyadenylation signal which regulates the termination of transcription.
- coding region or "structural gene” it is meant any region of DNA that determines the primary structure of a polypeptide following genetic transcription and translation. Furthermore, fragments comprising regions of interest of a coding region or structural gene may also be employed as needed.
- synthetic gene it is meant a DNA sequence of a structural gene that is synthesized chemically.
- a synthetic gene can comprise a fragment or the entire coding region of the gene of interest.
- a synthetic gene may also comprise regulatory elements that enhance expression of the gene, or motifs that aid in the stability of the protein product. It is also contemplated that a synthetic gene optionally includes regions useful for the isolation and purification of the protein, or the protein fragment, encoded by the synthetic gene.
- DNA regulatory region it is meant any region within a genomic sequence that has the property of controlling the expression of a DNA sequence that is operably linked with the regulatory region. Such regulatory regions may include promoter or - 14 - enhancer regions, and other regulatory elements recognized by one of skill in the art.
- promoter it is meant the nucleotide sequences at the 5' end of a coding region, or fragment thereof that contain all the signals essential for the initiation of transcription and for the regulation of the rate of transcription.
- the promoters used to exemplify the present invention are constitutive promoters that are known to those of skill in the art. However, if tissue specific expression of the gene is desired, for example seed, or leaf specific expression, then promoters specific to these tissues may also be employed.
- inducible promoters may also be used in order to regulate the expression of the gene following the induction of expression by providing the appropriate stimulus for inducing expression.
- the use of inducible promoters may be required as the use of constitutive synthesis of a foreign protein may in some cases be toxic or inhibit normal growth of the plant, with the result that the only plants which regenerate following transformation are those expressing very low levels of the foreign protein.
- inducer d e DNA sequences or genes will not be transcribed.
- the protein factor that binds specifically to an inducible promoter to activate transcription, is present in an inactive form which is then directly or indirectly converted to the active form by the inducer.
- the inducer can be a chemical agent such as a protein, metabolite, growth regulator, herbicide or phenolic compound or a physiological stress imposed directly by heat, cold, salt, or toxic elements or indirectly through the action of a pathogen or disease agent such as a virus.
- a plant cell containing an inducible promoter may be exposed to an inducer by externally applying the inducer to the cell or plant such as by spraying, watering, heating or similar methods.
- constitutive promoter it is meant a promoter that directs the expression of a gene throughout the various parts of a plant and continuously throughout plant development.
- Examples of known constitutive promoters include those associated with the CaMV 35S transcript and Agrobacterium Ti plasmid nopaline synthase gene. - 15 -
- the chimeric gene constructs of the present invention can further comprise a 3' untranslated region.
- a 3' untranslated region refers to that portion of a gene comprising a DNA segment that contains a polyadenylation signal and any other regulatory signals capable of effecting mRNA processing or gene expression.
- the polyadenylation signal is usually characterized by effecting the addition of polyadenylic acid tracks to the 3' end of the mRNA precursor.
- Polyadenylation signals are commonly recognized by d e presence of homology to the canonical form 5' AATAAA- 3' although variations are not uncommon.
- suitable 3' regions are the 3' transcribed non-translated regions containing a polyadenylation signal of Agrobacterium tumour inducing (Ti) plasmid genes, such as the nopaline synthase (Nos gene) and plant genes such as the soybean storage protein genes and the small subunit of the ribulose-1, 5-bisphosphate carboxylase (ssRUBISCO) gene.
- Ti Agrobacterium tumour inducing
- Nos gene nopaline synthase
- ssRUBISCO small subunit of the ribulose-1, 5-bisphosphate carboxylase
- the gene constructs of the present invention can also include further enhancers, either translation or transcription enhancers, as may be required.
- enhancer regions are well known to persons skilled in the art, and can include the ATG initiation codon and adjacent sequences.
- the initiation codon must be in phase with the reading frame of the coding sequence to ensure translation of the entire sequence.
- the translation control signals and initiation codons can be from a variety of origins, both natural and synthetic.
- Translational initiation regions may be provided from the source of the transcriptional initiation region, or from the structural gene.
- the sequence can also be derived from the promoter selected to express the gene, and can be specifically modified so as to increase translation of the mRNA.
- constructs of this invention may be further manipulated to include plant selectable markers.
- Useful selectable markers include enzymes which provide for resistance to an antibiotic such - 16 - as gentamycin, hygromycin, kanamycin, and the like.
- enzymes providing for production of a compound identifiable by colour change such as GUS ( ⁇ -glucuronidase), or luminescence, such as luciferase are useful.
- transformation it is meant the stable interspecific transfer of genetic information that is manifested phenotypically.
- the constructs of the present invention can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, micro-injection, electroporation, etc as would be known to those of skill in the art.
- transgenic plants containing the chimeric gene construct of the present invention are also considered part of this invention.
- Methods of regenerating whole plants from plant cells are known in the art, and the method of obtaining transformed and regenerated plants is not critical to this invention.
- transformed plant cells are cultured in an appropriate medium, which may contain selective agents such as antibiotics, where selectable markers are used to facilitate identification of transformed plant cells.
- an appropriate medium which may contain selective agents such as antibiotics, where selectable markers are used to facilitate identification of transformed plant cells.
- shoot formation can be encouraged by employing the appropriate plant hormones in accordance widi known methods and the shoots transferred to rooting medium for regeneration of plants.
- the plants may then be used to establish repetitive generations, either from seeds or using vegetative propagation techniques.
- cogniation optimization it is meant the selection of appropriate DNA nucleotides for the synthesis of oligonucleotide building blocks, and their subsequent enzymatic assembly, of a structural gene or fragment thereof in order to approach codon usage within plants.
- ORF5 protein it is meant one of the known two membrane-spanning envelope glycoproteins found within members of the Arterivirus family.
- ORF 5 gene was examined at the DNA level and then the coding region optimized for expression in plants using a procedure similar to that outlined by Sardana et al. 1996.
- the standard deviation of codon usage was calculated by first finding the squared proportional deviation of usage of each codon of the native ORF5 gene relative to that of highly expressed plant genes, followed by a calculation of the average squared deviation.
- the formula used is: - 18 -
- X n refers to the frequency of usage of codon n in highly expressed plant genes
- Y n to the frequency of usage of codon n in the gene of interest
- N refers to the total number of codons in the gene of interest.
- the synthetic PRRS virus ORF 5 gene of this invention is performed using standard technology know in the art.
- the ORF5 preprotein designed for increased expression in plants is assembled enzymatically, within a DNA vector, from chemically synthesized oligonucleotide duplex segments.
- the synthetic PRRS virus ORF5 gene is then transformed to plant genomes using methods known in the art. It is contemplated that a transgenic plant comprising the heterologous protein may be administered to an animal in a variety of ways depending upon the need and the situation. For example, if the protein is orally administered, the plant tissue may be harvested and directly feed to the animal, or the harvested tissue may be dried prior to feeding, or the animal may be permitted to graze on the plant with no prior harvest taking place.
- the harvested plant tissues may be provided as a food supplement within animal feed.
- the protein obtained from the transgenic plant may be extracted prior to its use as a food supplement, in either a crude, partially purified, or purified form. The administration of any of these protein forms to pigs, results in the formation of an antibody that protects the animal from the PRRS virus.
- SDCU standard deviation of codon usage
- the synthetic ORF5 gene was constructed by assembling three blocks of DNA of approximately 200 bp each (Block I, Block II, and Block III: see Figures 1 and 2 and sequences listed in Figure 4; Primers 1 to 12 of Figure 4 are SEQ ID NO's 2 to 13, respectively). Each block contained restriction site overhangs at the 5' and 3' ends for cloning purposes using standard techniques and allowing ligation of the synthetic blocks to form the complete ORF5 coding region.
- the completed ORF5 coding region contained 5' Ncol and BamHI restriction sites, and 3' BspHI and Kpnl restriction sites.
- the individual blocks of the ORF5 synthetic gene were constructed by designing overlapping oligonucleotides of approximately 60-90 bp in length utilizing codons typically used in highly expressed genes in plants (Fig. 3).
- the central pair of oligonucleotides (100 pmol each) were denatured together for 1 minute at 94 °C, cooled to 60 °C over 35 minutes to allow annealing, held at 60 °C for 5 minutes at which time 5.25 units of Expand DNA polymerase (Boehringer Mannheim) were added.
- the reaction mixture was then warmed to 68 °C over five minutes and the fill- in reaction proceeded for two hours at 68 °C.
- DNA fragment was then gel purified using standard methods.
- the PCR fragments corresponding to blocks 1, 2 and 3 were introduced into the pGEMTEasy cloning vector according to the manufactures recommended method.
- Blocks I, II and III were removed from the pGEMTEasy vector by digestion with restriction enzymes corresponding to the introduced enzyme sites at the 5' and 3' ends of the fragments.
- the fragments were assembled together into the complete synthetic gene by successive cloning steps into a pBluescript (KS+) cloning vector.
- KS+ pBluescript
- Blocks I, II, and III were liberated from the vector by digesting with BamHI and Hindlll, Hindlll and Xbal, Xbal and Kpnl, respectively.
- Blocks II and III were introduced simultaneously into pBluescript digested with Hindlll and Kpnl (tripartite ligation). This vector (pBS23) was then digested with BamHI and Hindlll and Block I was added to complete the synthetic gene.
- PRRS virus ORF5 genes were sequenced and found to encode the same protein as native ORF5 gene, except for the addition of the PRlb sequence, HIS tag sequence, or KDEL motif, as the case may be.
- pCAMTerX-ORF5A comprises a native ORF5 gene
- pCAMTerX-ORF5B contains the synthetic ORF5 mature protein coding region, the PRlb signal sequence and the KDEL ER retention motif;
- ORF5A and pPSP-ORF5B The native ORF5, or synthetic ORF5 genes were cloned into the pBI101.2 derived binary vector pBIS ⁇ l, which carries the superpromoter, to produce pPSP-ORF5A and pPSP-ORF5B:
- pPSP-ORF5A comprises the native gene
- pPSP-ORF5B contains the synthetic ORF5A mature protein coding region, the
- Infection with Agrobacterium strains each containing a vector comprising one of the five constructs identified above was achieved using overnight cultures grown in LB medium diluted by about 50% .
- the leaf explants were submerged quickly (about 30 seconds) and blotted on Whatman No.2 filter paper to remove excess bacteria. They are then returned to Media 1 for 2 days.
- the explants are transferred to media with 500 - 23 - ug/ml Timentin (SmithKline Beecham, Oakville) and the selective agent, 100 ug/ml kanamycin (Sigma, St. Louis).
- the explants are transferred to fresh media every 2- 3 weeks and shoots began to emerge within 3-5 weeks.
- the shoots are excised and transferred to Magenta boxes with solid media consisting of MS salts, B5 vitamins, 3% sucrose, 500 ug/ml cefotaxime or Timentin and 100 ug/ml kanamycin.
- solid media consisting of MS salts, B5 vitamins, 3% sucrose, 500 ug/ml cefotaxime or Timentin and 100 ug/ml kanamycin.
- the putative transgenic plants are transferred to the greenhouse. To ensure that each plant arises from an independent transformation event the explants are divided into separate fragments early in the procedure and only 1 shoot is selected from each fragment.
- Young petioles (3 youngest petioles per stem) were harvested from greenhouse- grown alfalfa plants, and sterilized by soaking in 75% ethanol for 30 seconds followed by soaking in 4% calcium hypochlorite for 20 minutes. The petioles were then rinsed with three changes of sterile water and cut into sections of 1cm in length. The petiole sections were dipped in Agrobacterium culture for 1 minute, removed from the bacterial culture and placed directly on induction medium (containing 100 ⁇ M acetosyringinone, no antibiotics) and incubated in the dark at 25°C for 2 days.
- induction medium containing 100 ⁇ M acetosyringinone, no antibiotics
- kanamycin 50 mg/L kanamycin and 1 % (w/v) sucrose.
- the green, elongated embryos were transferred to germination medium individually, without any attached callus, then laid on the media until roots, shoots and leaves develop. Individual plantlets were then placed in soil in pots and transferred to the greenhouse for further growth.
- transgene of Fig. 1 would use primers of sequence:
- DNA was extracted from plant tissue using standard methods and subjected to 30 cycles of amplification using 15pMol of both primers, 100 mM dNTPs, 2mM MgC12, 1U Taq polymerase and 50 ng of DNA template.
- DNA from positive plants was digested with a restriction enzyme that does not cut inside the T-DNA borders and subject to Southern analysis using the requisite transgene as a probe. Probes were randomly labelled using 50 uCi of [ ⁇ 32 P]CTP using standard methods. All washes were conducted at high stringency.
- RNA was first treated with RNase-free DNase and 2 ⁇ g was used for cDNA synthesis.
- Oligo dT (12-18) 05. ⁇ g was mixed with the RNA and heated to 90 °C, allowed to cool to 70 °C, and then chilled on ice.
- First strand synthesis proceeded for 50 min at 42°C in a buffer containing 10 mM DTT.
- Northern blot analysis was done with 20 ⁇ g RNA extracted from transgenic plants containing either the native or the synthetic ORF5 gene using standard techniques.
- the transcripts detected on d e Northern blots ranged in size from 1200 to 1400 bases for the native ORF5 and 1500 to 1800 bases for the synthetic ORF5 as compared to ⁇ HindHI fragments run on the same blots. These size estimates are larger than the native gene (602 bp) or synthetic gene (752 bp) presumably because of the additional sequence from the promoter (e.g. 35SCaMV, 250 bp), terminator (nos terminator 250 bp), and the poly A tail (unknown length).
- ORF5A construct 7 were found to express the ORF5 gene product ( Figure 6). - 26
- ELISA was used to quantify transgene protein yields.
- a monospecific polyclonal antibody for the ORF5 protein has been raised in rabbits using a GST-ORF5 fusion protein synthesized in E. coli.
- a polyclonal antibody raised in pigs against the whole PRRS virus has also been prepared. Botfi of these antibodies were used for protein expression studies as well as for ELISA for protein quantitation.
- Two routes of administration may be considered to elicit protective immunity in animals by the recombinant ORF5 protein produced in plants: intramuscular administration and oral administration.
- the four groups are comprised of two placebo groups immunized with normal plant extracts of either alfalfa or tobacco, a group immunized with alfalfa-ORF5 protein, and a group immunized with tobacco-ORF5 protein.
- Animals are bled prior to first immunization, and the preimmune antibody titres for PRRS virus are determined.
- Antigens are mixed with oil-based adjuvants, and approximately 100 ⁇ g of ORF5 protein is used per animal for intramuscular immunization at three-week intervals for a total of - 28 - three times.
- Peripheral blood samples are taken at 3 weeks, 6 weeks, and 8 weeks post- immunization, and examined for the development of specific antibody responses to the ORF5 protein and PRRS virus.
- Serum samples are analysed by enzyme-linked imm ⁇ no sorbent assay (ELISA) for the presence of specific antibodies to ORF5 protein.
- PRRS virus is grown in tissue culture and purified through discontinuous sucrose gradient centrifugation. The viral antigens are coated on the ELISA plates, and die IgG detection ELISA is performed. The serum samples are also examined for their ability to neutralize virus infectivity by plaque reduction neutralization assays. Lung lavages and gut washes are examined for the presence of secretory IgA antibodies and neutralizing titers.
- ELISA enzyme-linked imm ⁇ no sorbent assay
- PRRS virus-coated plates are incubated with the gut washes or lung lavages at various dilutions, and the antigen-antibody complexes are incubated with the secondary anti-porcine IgA antibody.
- Anti-secondary antibody conjugate and chromogenic substance are added for colour developments.
- Ability of the secretory IgA for virus neutralization is also examined by PRRS virus plaque reduction assays.
- Lactate dehydrogenase-elevating virus equine arteritis virus, and simian hemorragic fever virus: A new group of positive- stranded RNA viruses. Adv. Virus Res. 41: 99-192.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99901552A EP1066383A1 (en) | 1998-01-27 | 1999-01-27 | Porcine reproductive and respiratory syndrome oral vaccine production in plants |
AU21468/99A AU2146899A (en) | 1998-01-27 | 1999-01-27 | Porcine reproductive and respiratory syndrome oral vaccine production in plants |
CA002319141A CA2319141A1 (en) | 1998-01-27 | 1999-01-27 | Porcine reproductive and respiratory syndrome oral vaccine production in plants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002221843A CA2221843A1 (en) | 1998-01-27 | 1998-01-27 | Porcine reproductive and respiratory syndrome oral vaccine production in plants |
CA2,221,843 | 1998-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999037784A1 true WO1999037784A1 (en) | 1999-07-29 |
Family
ID=4161793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1999/000064 WO1999037784A1 (en) | 1998-01-27 | 1999-01-27 | Porcine reproductive and respiratory syndrome oral vaccine production in plants |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1066383A1 (en) |
CN (1) | CN1295618A (en) |
AU (1) | AU2146899A (en) |
CA (1) | CA2221843A1 (en) |
WO (1) | WO1999037784A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1409011A1 (en) * | 2000-01-21 | 2004-04-21 | Alfred Hospital | Prime-boost vaccination strategy |
US7329798B2 (en) | 2002-06-28 | 2008-02-12 | University Of Guelph | Harvest-inducible regulatory elements and methods of using same |
US7388091B2 (en) | 2002-06-28 | 2008-06-17 | University Of Guelph | Harvest-inducible genes from alfalfa (Medicago sativa) and methods of use thereof |
EP2390256A1 (en) | 2001-05-30 | 2011-11-30 | Agrisoma, Inc. | Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2096529A1 (en) * | 1995-04-26 | 1997-03-01 | Univ Madrid Complutense | Process for the preparation and purification of the protein coded by ORF-5 in porcine reproductive and respiratory syndrome virus by affinity chromatography |
-
1998
- 1998-01-27 CA CA002221843A patent/CA2221843A1/en not_active Abandoned
-
1999
- 1999-01-27 WO PCT/CA1999/000064 patent/WO1999037784A1/en not_active Application Discontinuation
- 1999-01-27 EP EP99901552A patent/EP1066383A1/en not_active Withdrawn
- 1999-01-27 CN CN99804564.0A patent/CN1295618A/en active Pending
- 1999-01-27 AU AU21468/99A patent/AU2146899A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2096529A1 (en) * | 1995-04-26 | 1997-03-01 | Univ Madrid Complutense | Process for the preparation and purification of the protein coded by ORF-5 in porcine reproductive and respiratory syndrome virus by affinity chromatography |
Non-Patent Citations (8)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1409011A1 (en) * | 2000-01-21 | 2004-04-21 | Alfred Hospital | Prime-boost vaccination strategy |
EP1409011A4 (en) * | 2000-01-21 | 2005-09-21 | Hospital Alfred | Prime-boost vaccination strategy |
EP2390256A1 (en) | 2001-05-30 | 2011-11-30 | Agrisoma, Inc. | Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
US7329798B2 (en) | 2002-06-28 | 2008-02-12 | University Of Guelph | Harvest-inducible regulatory elements and methods of using same |
US7388091B2 (en) | 2002-06-28 | 2008-06-17 | University Of Guelph | Harvest-inducible genes from alfalfa (Medicago sativa) and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1066383A1 (en) | 2001-01-10 |
CN1295618A (en) | 2001-05-16 |
CA2221843A1 (en) | 1999-07-27 |
AU2146899A (en) | 1999-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Satyavathi et al. | Expression of hemagglutinin protein of Rinderpest virus in transgenic pigeon pea [Cajanus cajan (L.) Millsp.] plants | |
CA2651907C (en) | Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants | |
JP6828949B2 (en) | Vaccine antigen with enhanced immunogenicity | |
KR101540496B1 (en) | Bacterial toxin vaccine | |
JP2010241817A (en) | New immunoadhesin for treating and preventing toxicity and pathogen-mediated disease | |
JP5279089B2 (en) | Pig edema disease vaccine | |
US20050166290A1 (en) | Expression cassettes and methods for delivery of animal vaccines | |
Prasad et al. | Expression of biologically active Hemagglutinin-neuraminidase protein of Peste des petits ruminants virus in transgenic pigeonpea [Cajanus cajan (L) Millsp.] | |
JP3174048B2 (en) | Transgenic plants belonging to Cucumis Melo species | |
US11566255B2 (en) | Expression of PEDV sequences in plants and plant produced vaccine for same | |
JP5008811B2 (en) | Immunoadhesives to prevent rhinovirus infection | |
JP2002532114A (en) | Transgenic plants and methods for producing them | |
EP1066383A1 (en) | Porcine reproductive and respiratory syndrome oral vaccine production in plants | |
US8557246B2 (en) | Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof | |
EP1290201B1 (en) | Recombinant subunit proteins from porcine parvovirus produced in plants | |
PL189499B1 (en) | Method of inducing immunity against viruses in a plant | |
TW201609130A (en) | Prevention of escherichia coli diarrhea | |
CA2319141A1 (en) | Porcine reproductive and respiratory syndrome oral vaccine production in plants | |
KR20120066559A (en) | Transformants expressing epitope of porcine epidemic diarrhea virus and rotavirus and vaccine composition containing the same | |
WO2002039808A1 (en) | Method of enhancing virus-resistance in plants and producing virus-immune plants | |
WO2004050692A2 (en) | Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production | |
JP2003116385A (en) | Transgenic plant containing gene encoding japanese b encephalitis vaccine | |
VIRUS | ONTARIO RESEARCH ENHANCEMENT PROGRAM (OREP) | |
CA2272793A1 (en) | Porcine transmissible gastroenteritis virus oral vaccine production in plants | |
JP2000139473A (en) | Recombinant plant into which rotavirus was introduced, protein of rotavirus derived from the recombinant plant and antibody against the protein of rotavirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99804564.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09626085 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2319141 Country of ref document: CA Ref document number: 2319141 Country of ref document: CA Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999901552 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999901552 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999901552 Country of ref document: EP |